Research & Development

Creating future value

Acrux is developing and marketing a range of topically applied products. Acrux has a growing portfolio of FDA approved Abbreviated New Drug Applications (ANDAs) including Testosterone Topical Solution 30mg /1.5ml, Efinaconazole Solution 10% and Lidocaine and Prilocaine Cream USP, 2.5%/2.5%. and an expanding pipeline of products under development. Acrux uses its internal development capabilities and know-how to develop generics which target a substantial portion of the US topical market. The development time required for generic products is substantially shorter and less costly than the length of time required for a new drug development.